Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
10
×
Tags
biotech
10
×
boston blog main
boston top stories
cancer
10
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
10
×
indiana blog main
indiana top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
deals
eli lilly
investing
startups
cancer immunotherapy
novartis
pfizer
roche
abbvie
alzheimer's disease
bristol-myers squibb
What
drug
10
×
roundup
bio
cancer
companies
fda
alzheimer’s
annual
approval
attention
biotech
latest
market
medicines
nash
new
news
patients
plan
price
prices
research
week
acquisitions
address
advantages
ahead
ambien
american
approved
approves
asco
assessed
attendees
bar
biggest
biogen’s
biopharmaceutical
blueprint
brings
Language
unset
Current search:
cancer
×
biotech
×
" san francisco top stories "
×
photo
×
drug
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More